ArticleJournal of cancer research and clinical oncology2009
Reduced expression of C/EBP alpha protein in hepatocellular carcinoma is associated with advanced tumor stage and shortened patient survival.
Article in Journal of cancer research and clinical oncology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 46 citations in OpenAlex.
- Integrated transcriptomic analysis reveals a CEBPB-DUSP1 axis driving tumor progression in colorectal cancer.PloS one · 2025Article
- Super-enhancers complexes zoom in transcription in cancer.Journal of experimental & clinical cancer research : CR · 2023Review
- MicroRNA-128 suppresses tau phosphorylation and reduces amyloid-beta accumulation by inhibiting the expression of GSK3β, APPBP2, and mTOR in Alzheimer's disease.CNS neuroscience & therapeutics · 2023Article
- Modulating the expression of tumor suppressor genes using activating oligonucleotide technologies as a therapeutic approach in cancer.Molecular therapy. Nucleic acids · 2023Review
- Review
- Genetic Polymorphisms of lncRNAInternational journal of molecular sciences · 2022Article
- Computational modeling of chromatin accessibility identified important epigenomic regulators.BMC genomics · 2022Article
- The "Janus" Role of C/EBPs Family Members in Cancer Progression.International journal of molecular sciences · 2020Review
- Identification of the possible therapeutic targets in the insulin-like growth factor 1 receptor pathway in a cohort of Egyptian hepatocellular carcinoma complicating chronic hepatitis C type 4.Drug target insights · 2020Article
- Article
- C/EBPα mediates the growth inhibitory effect of progestins on breast cancer cells.The EMBO journal · 2019Article
- Anti-inflammatory Activity of MTL-CEBPA, a Small Activating RNA Drug, in LPS-Stimulated Monocytes and Humanized Mice.Molecular therapy : the journal of the American Society of Gene Therapy · 2019Article
- Upregulation of C/EBPα contributes to colorectal cancer growth, metastasis and indicates poor survival outcome.American journal of cancer research · 2018Article
- Development and Mechanism of Small Activating RNA Targeting CEBPA, a Novel Therapeutic in Clinical Trials for Liver Cancer.Molecular therapy : the journal of the American Society of Gene Therapy · 2017Article
- Review
- IL-17 promotes keratinocyte proliferation via the downregulation of C/EBPα.Experimental and therapeutic medicine · 2016Article
- Yin Yang-1 suppresses differentiation of hepatocellular carcinoma cells through the downregulation of CCAAT/enhancer-binding protein alpha.Journal of molecular medicine (Berlin, Germany) · 2012Article
- Article
- Decreased expression of p39 is associated with a poor prognosis in human hepatocellular carcinoma.Medical oncology (Northwood, London, England) · 2011Article
- Intracellular signaling and hepatocellular carcinoma.Seminars in cancer biology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCCAAT/enhancer binding protein alpha (C/EBP alpha) is a transcription factor and a tumor suppressor. We aimed to assess its protein expression and prognostic value in human hepatocellular carcinoma (HCC).
methodsWe conducted a retrospective cohort study on 50 HCC patients and performed immunohistochemistry against C/EBP alpha on tumors and adjacent nontumor specimens. Relationships of C/EBP alpha expression with clinical parameters and patient survival were analyzed.
resultsC/EBP alpha expression was not influenced by chronic alcohol exposure, viral hepatitis, or cirrhosis, but was reduced in 60% of HCC. Reduction of C/EBP alpha was associated with advanced tumor stage (P = 0.001). Patients with markedly reduced C/EBP alpha expression had a significantly shorter survival with a hazard ratio of 5.45 (95% confidence interval, 1.93-15.40; P = 0.001).
conclusionsC/EBP alpha may be a potential prognostic marker or therapeutic target in HCC regardless of different etiology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.